Foster City, CA, United States of America

Shahul Nilar

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Shahul Nilar: Innovator in Ferroportin Inhibitors

Introduction

Shahul Nilar is a prominent inventor based in Foster City, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target iron metabolism disorders. With a total of three patents to his name, Nilar's work is paving the way for innovative treatments in this critical area of healthcare.

Latest Patents

Nilar's latest patents focus on cycloalkyl pyrimidines as ferroportin inhibitors. The subject matter described in these patents is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof. These patents detail methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the prophylaxis and treatment of diseases caused by a lack of hepcidin or iron metabolism disorders. This includes conditions such as thalassemia, sickle cell disease, hemochromatosis, and kidney injuries.

Career Highlights

Shahul Nilar is currently employed at Global Blood Therapeutics, Inc., where he continues to advance his research and development efforts. His work is instrumental in addressing critical health issues related to iron overload states and improving patient outcomes.

Collaborations

Nilar collaborates with talented coworkers, including Zhe Li and Qing Xu, who contribute to the innovative environment at Global Blood Therapeutics, Inc. Their combined expertise enhances the potential for groundbreaking discoveries in the field.

Conclusion

Shahul Nilar's contributions to the development of ferroportin inhibitors represent a significant advancement in the treatment of iron metabolism disorders. His innovative work continues to inspire progress in pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…